Post-ASH 2022 iwMDS

12 January 2023 | Virtual Meeting

Expert-led presentations & discussions on key abstracts in myelodysplastic syndromes (MDS) from ASH 2022

The Post-ASH 2022 iwMDS Virtual Workshop was held on 12 January 2022. The program covered the latest in MDS and featured a series of short presentations from invited experts on selected abstracts from the 64th ASH Annual Meeting with interactive panel discussions after each session.

Prognostic factors in MDS Classification of MDS and disease characteristics Lower risk MDS Higher risk MDS

Session 1: prognostic factors in MDS

Phase I results of SX-682 in patients with hypomethylating agent failure MDS

David Sallman H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States

Matteo Della Porta

Real-world validation of IPSS-M for MDS

Matteo Della Porta Humanitas Research Hospital, Milan, Italy

Session 1 panel discussion

Session 2: classification of MDS and disease characteristics

Validation of 2022 WHO and ICC classifications

Somedeb Ball H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States

Marcelo Iastrebner

MDS in Latin America - results from a novel international registry: Re-Glam

Marcelo Iastrebner Sanatorio Sagrado Corazón, Buenos Aires, Argentina

Panel discussion 2

Content to be uploaded soon

Session 3: lower risk MDS

Synergistic activity of luspatercept & ESAs for treatment of anemia in LR-MDS

David Sallman H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States

Luspatercept for HMA and len-treated patients with LR-MDS: real-world data

Rami Komrokji H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States

Clinical & biological effects of canakinumab in LR-MDS: Phase II trial

Simona Colla University of Texas MD Anderson Cancer Center, Houston, TX, United States

ASTX727-03: Phase I study evaluating ASTX727 low-dose in LR-MDS

David Sallman H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States

Panel discussion 3

Valeria Santini

MEDALIST trial: OS and PFS of patients following treatment with luspatercept

Valeria Santini University of Florence, Florence, Italy

María Díez Campelo

Sintra-REV: len vs placebo in non-transfusion dependent del(5q) LR-MDS

María Díez Campelo University of Salamanca, Salamanca, Spain

Uwe Platzbecker

IMerge: imetelstat in patients with transfused non-del(5q) LR-MDS R/R to ESAs

Uwe Platzbecker University Hospital in Leipzig, Leipzig, Germany

Panel discussion 4

Session 4: higher risk MDS

Primary results of Stimulus-MDS1: sabatolimab added to HMAs in HR-MDS

Amer Zeidan Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States

Results of Phase II multicenter trial of ruxolitinib in symptomatic CMML

Eric Padron Moffitt Cancer Center, Tampa, FL, United States

Panel discussion 5

For the latest updates in myelodysplastic syndromes, visit The MDS Channel